Additionally, the observed cost differences across biomarker-defined subgroups, particularly those related to APOE, Aß status, or hypertension, highlight the complex interplay between biological and clinical factors in shaping healthcare utilization and costs. This evidence concerns the gene APOE and hypertensive disorder.